Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials

PURPOSE: The yield of comprehensive genomic profiling in recruiting patients to molecular-based trials designed for small subgroups has not been fully evaluated. We evaluated the likelihood of enrollment in a clinical trial that required the identification of a specific genomic change based on our i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Exman, Pedro, Garrido-Castro, Ana C., Hughes, Melissa E., Freedman, Rachel A., Li, Tianyu, Trippa, Lorenzo, Bychkovsky, Brittany L., Barroso-Sousa, Romualdo, Di Lascio, Simona, Mackichan, Colin, Lloyd, Max R., Krevalin, Max, Cerami, Ethan, Merrill, Margaret S., Santiago, Rebecca, Crowley, Lindsey, Kuhnly, Nicole, Files, Janet, Lindeman, Neal I., MacConaill, Laura E., Kumari, Priti, Tolaney, Sara M., Krop, Ian E., Bose, Ron, Johnson, Bruce E., Ma, Cynthia X., Dillon, Deborah A., Winer, Eric P., Wagle, Nikhil, Lin, Nancy U.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446367/
https://ncbi.nlm.nih.gov/pubmed/32923853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00087
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados